MedTrace Logo

Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

NCT07243015 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-11-21

No results posted yet for this study

Summary

Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.

Conditions

Interventions

DIAGNOSTIC_TEST

small RNA-seq or array

small RNA-seq or array

DIAGNOSTIC_TEST

ENLIGHT Assay

RT-qPCR-based exo-miRNA quantification

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2026-06-18
Completion
2026-06-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07243015 on ClinicalTrials.gov